ENTROPY NEURODYNAMICS LIMITED — Capital/Financing Update 2024

May 27, 2024

Market Announcement

==> picture [33 x 50] intentionally omitted <==

28 May 2024

==> picture [451 x 5] intentionally omitted <==

Tryptamine Therapeutics Ltd (ASX: TYP) – Formerly Exopharm Ltd – Amended Anticipated Reinstatement to Quotation

Description

It is anticipated the securities of Tryptamine Therapeutics Ltd (‘TYP’) will be reinstated to quotation at Wednesday, 29 May 2024 following its re-compliance with Chapters 1 and 2 of the ASX Listing Rules.

TYP raised $6,500,000 pursuant to the offer under its replacement prospectus dated 28 March 2024 by the issue of 325,000,000 shares at an issue price of $0.02 per share.

Quotation information

Quoted securities	Fully paid ordinary shares: 1,089,048,588
ASX code	Fully paid ordinary shares: TYP
Time	10:04:30am (+/- 15 seconds) AEST
Date	Wednesday, 29 May 2024
ASX trade abbreviation	Fully paid ordinary shares: TRYPTAMINE
ISIN	Fully paid ordinary shares: AU0000331993
Registered office	C/- Bio101 Financial Advisory Pty LtdSuite 201, 697 Burke RoadCamberwell VIC 3124Phone: (03) 8419 0827Email: david.franks@automicgroup.com.au
Company secretary	David Franks
Share Registry	Automic GroupLevel 5, 126 Phillip StreetSydney NSW 2000
Balance date	30 June
CHESS	Participating. CHESS and Issuer Sponsored.
Place of incorporation	Australia
Dividend policy	See section 62 of the Replacement Prospectus
Activities	Research and development of pharmaceuticals and biotechnology
Lead manager	Alto Capital
Underwriter	N/A
ASX restricted securities	24 Month Escrow

Market Announcement 1/3 ASX Customer Service Centre 131 279 | asx.com.au

28 May 2024 ASX Limited

#10737659v4

==> picture [33 x 50] intentionally omitted <==

49,873,318 fully paid ordinary shares classified by ASX as restricted securities and to be held in escrow until 29 May 2026, being 24 months from the date of Quotation.

36,160,000 options exercisable at $0.03125 on or before 22 April 2027, classified by ASX as restricted securities and to be held in escrow until 29 May 2026, being 24 months from the date of Quotation.

30,604,190 options exercisable at $0.0338 on or before 30 October 2028, classified by ASX as restricted securities and to be held in escrow until 29 May 2026, being 24 months from the date of Quotation.

18,803,200 options exercisable at $0.0531 on or before 29 May 2029, being 5 years from the date of reinstatement, classified by ASX as restricted securities and to be held in escrow until 29 May 2026, being 24 months from the date of Quotation.

118,683,780 options exercisable at $0.027 on or before 29 May 2027, being 3 years from the date of reinstatement, classified by ASX as restricted securities and to be held in escrow until 29 May 2026, being 24 months from the date of Quotation.

12 Month Escrow

2,892,800 options exercisable at $0.0531 on or before 22 July 2024, classified by ASX as restricted securities and to be held in escrow until 1 May 2025, being 12 months from the date of issue.

2,892,800 options exercisable at $0.0469 on or before 20 September 2025, classified by ASX as restricted securities and to be held in escrow until 1 May 2025, being 12 months from the date of issue.

15,439,178 options exercisable at $0.0469 on or before 29 May 2029, being 5 years from the date of reinstatement, classified by ASX as restricted securities and to be held in escrow until 1 May 2025, being 12 months from the date of issue.

8,316,800 options exercisable at $0.0531 on or before 29 May 2029, being 5 years from the date of reinstatement, classified by ASX as restricted securities and to be held in escrow until 1 May 2025, being 12 months from the date of issue.

7,232,000 options exercisable at $0.0338 on or before 30 October 2028, classified by ASX as restricted securities and to be held in escrow until 1 May 2025, being 12 months from the date of issue.

1,808,000 options exercisable at $0.06250 on or before 8 July 2027, classified by ASX as restricted securities and to be held in escrow until 1 May 2025, being 12 months from the date of issue.

361,600 options exercisable at $0.2125 on or before 29 May 2029, being 5 years from the date of reinstatement, classified by ASX as restricted securities and to be held in escrow until 1 May 2025, being 12 months from the date of issue.

191,735,780 options exercisable at $0.027 on or before 29 May 2027, being 3 years from the date of reinstatement, classified by ASX as restricted securities and to be held in escrow until 1 May 2024, being 12 months from the date of issue.

Other securities not quoted

600,000 options exercisable at $1.00 on or before 9 November 2025.

Market Announcement 2/3

28 May 2024

#10737659v4

==> picture [33 x 50] intentionally omitted <==

600,000 options exercisable at $1.50 on or before 9 November 2025. 600,000 options exercisable at $2.25 on or before 9 November 2025. 1,200,000 options exercisable at $0.025 on or before 12 May 2026. 4,000,000 options exercisable at $0.0375 on or before 1 December 2027. 2,000,000 options exercisable at $0.05 on or before 1 December 2027. 2,000,000 options exercisable at $0.075 on or before 1 December 2027.

What do I need to do and by when?

For further information, please refer to TYP’s Replacement Prospectus.

Need more information?

For further information, please call Tryptamine Therapeutics Ltd on (03) 8419 0827.

Disclaimer

Please refer to the following disclaimer.

Issued by

ASX Compliance

Market Announcement 3/3

28 May 2024

#10737659v4